<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634569</url>
  </required_header>
  <id_info>
    <org_study_id>IG-0705</org_study_id>
    <nct_id>NCT00634569</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grifols Biologicals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label study to assess the efficacy and safety of Flebogamma 5%
      DIF in the pediatric population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Bacterial Infections.</measure>
    <time_frame>12 months</time_frame>
    <description>Total number of Bacterial pneumonia, bacteremia or sepsis, osteomyelitis/septic arthritis, visceral abscess or bacterial meningitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of School/Usual Activities Missed Per Year</measure>
    <time_frame>12 months</time_frame>
    <description>Mean Days of school/usual activities missed per subject/year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Hospitalization Per Year</measure>
    <time_frame>12 months</time_frame>
    <description>Mean Days of hospitalization per subject/year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Visits to Physician/ER Room for Acute Problems</measure>
    <time_frame>12 months</time_frame>
    <description>Mean Number of visits to physician/ER room for acute problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Infections Documented by Fever and Physical Exam or Positive Radiograph.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infectious Episodes Per Year</measure>
    <time_frame>12 months</time_frame>
    <description>Mean Number of infectious episodes per subject/year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days on Antibiotics (Prophylactic and Therapeutic).</measure>
    <time_frame>12 months</time_frame>
    <description>Median Combined number of days on prophylactic and therapeutic antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Total Number of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Primary Immune Deficiency Disease</condition>
  <arm_group>
    <arm_group_label>Flebogamma 5% DIF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flebogamma 5% DIF</intervention_name>
    <description>Intravenous Immune Globulin (Human)</description>
    <arm_group_label>Flebogamma 5% DIF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject is between 2 and 16 years old, of either sex, belonging to any ethnic
             group, and above a minimum weight of 10 kg (this weight is based on the amount of
             blood required for testing).

          -  The subject has a primary immunodeficiency disease, (e.g., common variable
             immunodeficiency, X-linked and autosomal forms of agammaglobulinemia, hyper-IgM
             syndrome, Wiskott-Aldrich Syndrome).

          -  The subject has been receiving licensed IGIV replacement therapy at a dose that has
             not changed by + 50% of the mean dose on a mg/kg basis for at least 3 months before
             study entry and has maintained a trough level at least 300 mg/dL above baseline serum
             IgG levels.

          -  Trough levels of IgG, dose of IGIV, and treatment intervals for the last 2 consecutive
             routine IGIV treatments must be documented for each subject before the first infusion
             in this study can be administered.

          -  If a subject is an adolescent female (&gt; 12 years of age) who is or becomes sexually
             active, she must have a negative result on a pregnancy test (HCG-based assay).

          -  The subject, if old enough (generally 6 years to 16) has signed an informed Child
             Assent form and the subject's parent or legal guardian has signed an informed consent
             form, both approved by the Institutional Review Board.

        Exclusion Criteria:

          -  Adult patient (&gt; 17 years old).

          -  The subject has a history of any severe anaphylactic reaction to blood or any
             blood-derived product.

          -  The subject is known to be intolerant to any component of the products, such as
             sorbitol (i.e., intolerance to fructose).

          -  The subject has selective IgA deficiency or has demonstrable antibodies to IgA.

          -  The subject is currently receiving, or has received, any investigational agent within
             the prior 3 months.

          -  The subject has been exposed to blood or any blood product or derivative within the
             last 6 months, other than a commercially available IGIV.

          -  The adolescent subject is pregnant or is nursing.

          -  The subject, at screening, has levels greater than 2.5 times the upper limit of normal
             as defined at the central laboratory for pediatric patients of any of the following:

               -  ALT

               -  AST

               -  LDH

          -  The subject has a severe pre-existing renal impairment (defined by serum creatinine
             greater than 2 times the ULN or BUN greater than 2.5 times the ULN for that
             laboratory, or any subject who is on dialysis) or any history of acute renal failure.

          -  The subject has a history of DVT or thrombotic complications of IGIV therapy.

          -  The subject suffers from any acute or chronic medical condition (e.g., renal disease
             or predisposing conditions for renal disease, coronary artery disease, or protein
             losing state) that, in the opinion of the Investigator, may interfere with the conduct
             of the study.

          -  The subject has an acquired medical condition such as lymphocytic leukemia, chronic or
             recurrent neutropenia (ANC less than 1000), or AIDS known to cause secondary immune
             deficiency, or is s/p hematopoetic stem cell transplantation.

          -  The subject is receiving the following medication:

               -  Systemic corticosteroids (long-term, i.e., not intermittent or burst, daily, &gt; 1
                  mg of prednisone equivalent/kg/day). Topical steroids (ie- nasal, inhaled for
                  asthma, and/or skin preparations for eczema) are not exclusionary.

               -  Immunosuppressive drugs

               -  Immunomodulatory drugs

          -  The subject has non-controlled arterial hypertension (systolic blood pressure &gt; 160 mm
             Hg and/or diastolic blood pressure &gt; 100 mm Hg).

          -  The subject has anemia (hemoglobin &lt; 10 g/dL) at screening.

          -  The subject and/or parent/legal guardian of the subject is unlikely to adhere to the
             protocol requirements of the study or is likely to be uncooperative or unable to
             provide from the patient a storage serum sample at the screening visit. (Please note,
             a pre-treatment serum sample to be stored at -94° F (-70º C) for possible future
             testing is absolutely required).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Ballow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701-4899</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy &amp; Asthma Center, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Allergy and Asthma Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania State University, Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medial Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-7110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <results_first_submitted>May 20, 2015</results_first_submitted>
  <results_first_submitted_qc>October 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2016</results_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CVID, XLA, hyper IgM syndrome, Wiskott-Aldrich Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>21-day Dosing</title>
          <description>IGIV given every 21-days (225-600 mg/kg)</description>
        </group>
        <group group_id="P2">
          <title>28-day Dosing</title>
          <description>IGIV given every 28-days (300-800 mg/kg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>21-day Dosing</title>
          <description>IGIV given every 21-days (225-600 mg/kg)</description>
        </group>
        <group group_id="B2">
          <title>28-day Dosing</title>
          <description>IGIV given every 28-days (300-800 mg/kg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="4.3"/>
                    <measurement group_id="B2" value="9.7" spread="4.9"/>
                    <measurement group_id="B3" value="9.0" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serious Bacterial Infections.</title>
        <description>Total number of Bacterial pneumonia, bacteremia or sepsis, osteomyelitis/septic arthritis, visceral abscess or bacterial meningitis</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>21-day Dosing</title>
            <description>IGIV given every 21-days (225-600 mg/kg)</description>
          </group>
          <group group_id="O2">
            <title>28-day Dosing</title>
            <description>IGIV given every 28-days (300-800 mg/kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Bacterial Infections.</title>
          <description>Total number of Bacterial pneumonia, bacteremia or sepsis, osteomyelitis/septic arthritis, visceral abscess or bacterial meningitis</description>
          <units>Total serious bacterial infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of School/Usual Activities Missed Per Year</title>
        <description>Mean Days of school/usual activities missed per subject/year</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Intent-to-treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Days of School/Usual Activities Missed Per Year</title>
          <description>Mean Days of school/usual activities missed per subject/year</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Hospitalization Per Year</title>
        <description>Mean Days of hospitalization per subject/year</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Intent-to-treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Days of Hospitalization Per Year</title>
          <description>Mean Days of hospitalization per subject/year</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Visits to Physician/ER Room for Acute Problems</title>
        <description>Mean Number of visits to physician/ER room for acute problems</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Intent-to-treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Visits to Physician/ER Room for Acute Problems</title>
          <description>Mean Number of visits to physician/ER room for acute problems</description>
          <units>Visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Infections Documented by Fever and Physical Exam or Positive Radiograph.</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Intent-to-treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Other Infections Documented by Fever and Physical Exam or Positive Radiograph.</title>
          <units>Number of other infections</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infectious Episodes Per Year</title>
        <description>Mean Number of infectious episodes per subject/year</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Intent-to-treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infectious Episodes Per Year</title>
          <description>Mean Number of infectious episodes per subject/year</description>
          <units>Infectious episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days on Antibiotics (Prophylactic and Therapeutic).</title>
        <description>Median Combined number of days on prophylactic and therapeutic antibiotics</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Intent-to-treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days on Antibiotics (Prophylactic and Therapeutic).</title>
          <description>Median Combined number of days on prophylactic and therapeutic antibiotics</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" spread="150.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <description>Total Number of Adverse Events</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Intent-to-treat population</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Total Number of Adverse Events</description>
          <units>All Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Systematic temporal assessment of AEs (by vital sign measurement up to 72 hours post-infusion) occurring over 1 year</desc>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>Intent-to-treat population</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="31" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diastolic hypotension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul J. Pinciaro, PhD</name_or_title>
      <organization>Grifols</organization>
      <phone>410-814-7617</phone>
      <email>paul.pinciaro@grifols.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

